title: Hyperlipidemia in childhood nephrotic syndrome.
abstract: Hyperlipidemia is an important characteristic of nephrotic syndrome (NS). Elevation of plasma total cholesterol, or more specifically low-density lipoprotein cholesterol, is the major lipid abnormality in NS, although hypertriglyceridemia may develop as the disorder progresses. The pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that both hepatic synthesis of lipids and of apolipoproteins is increased, and that the clearance of chylomicrons and very low-density lipoproteins is reduced. The precise contribution of increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic pressure remain controversial. There are two potential risks of elevated plasma lipids: atherosclerosis and progression of glomerular injury. Although neither of these complications has been proved with certainty, there is growing evidence that both may be long-term consequences of NS. Therefore, the diagnosis and treatment of lipid abnormalities, important aspects of the management of nephrotic children, is summarized here to provide pediatric nephrologists with an informed choice.
authors.affiliation: Nephrology Division, Children's Medical Center, Richmond, Virginia.
authors.forename: M A
authors.initials: MA
authors.lastname: Thabet
authors.forename: J R
authors.initials: JR
authors.lastname: Salcedo
authors.forename: J C
authors.initials: JC
authors.lastname: Chan
mesh_terms: D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D008055:Lipids / Q000097:blood; D009404:Nephrotic Syndrome / Q000150:complications* / Q000503:physiopathology / Q000628:therapy
chemical_list: D008078:Cholesterol, LDL; D008055:Lipids; D002784:Cholesterol